AR062011A1 - Derivados de diazol y sus composiciones como inhibidores de itpkb - Google Patents
Derivados de diazol y sus composiciones como inhibidores de itpkbInfo
- Publication number
- AR062011A1 AR062011A1 ARP070103248A ARP070103248A AR062011A1 AR 062011 A1 AR062011 A1 AR 062011A1 AR P070103248 A ARP070103248 A AR P070103248A AR P070103248 A ARP070103248 A AR P070103248A AR 062011 A1 AR062011 A1 AR 062011A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- substituted
- halogen
- hydrogen
- independently selected
- Prior art date
Links
- 101000852593 Homo sapiens Inositol-trisphosphate 3-kinase B Proteins 0.000 title 1
- 102100036404 Inositol-trisphosphate 3-kinase B Human genes 0.000 title 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical class C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 16
- 229910052736 halogen Inorganic materials 0.000 abstract 10
- 150000002367 halogens Chemical group 0.000 abstract 10
- 229910052739 hydrogen Inorganic materials 0.000 abstract 9
- 239000001257 hydrogen Substances 0.000 abstract 9
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 6
- 125000000217 alkyl group Chemical group 0.000 abstract 5
- 150000001875 compounds Chemical class 0.000 abstract 5
- 125000001072 heteroaryl group Chemical group 0.000 abstract 5
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 4
- 150000002431 hydrogen Chemical group 0.000 abstract 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 3
- 125000000041 C6-C10 aryl group Chemical group 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- 125000003118 aryl group Chemical class 0.000 abstract 2
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 150000001721 carbon Chemical group 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 125000006652 (C3-C12) cycloalkyl group Chemical group 0.000 abstract 1
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 1
- 108010048077 Inositol 1,4,5-trisphosphate 3-kinase Proteins 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 210000003719 b-lymphocyte Anatomy 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- -1 cyano, hydroxyl Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Composiciones farmacéuticas que comprenden estos compuestos, y métodos para utilizar tales compuestos con el fin de tratar o prevenir las enfermedades o trastornos asociados con actividades de células B anormales o mal reguladas, en particular enfermedades o trastornos que involucren una activación al errante de la 3-cinasa B de 1,4,5-trifosfato de inositol (ITPKb). Reivindicación 1: Un compuesto de la fórmula (1) en donde: n se selecciona a partir de 0, 1, 2 y 3; m se selecciona a partir de 0, 1, 2 y 3; A puede tener hasta 3 grupos seleccionados a partir de -CR¹=, -CR²=, -CR³=, -CR⁴= y -CR⁵= reemplazados con N; R¹, R², R³, R⁴ y R⁵ se seleccionan independientemente a partir de hidrógeno, hidroxilo, halógeno, ciano, alquilo C₁₋₆, alquilo C₁₋₆ sustituido por halógeno, alquilo C₁₋₆ sustituido por hidroxilo, alquilo C₁₋₆ sustituido por ciano, heterocicloalquilo C₃₋₈-alquilo C₀₋₄, heteroarilo C₁₋₁₀-alquilo C₀₋₄, -XSO₂R¹¹, -XSO₂NR¹¹R¹², -XSO₂NR¹¹C(O)R¹², -XC(NR¹¹)NR¹¹OR¹², -XCR¹¹=NOR¹², -XC(O)R¹¹, -XC(O)OR¹¹, -XNR¹¹R¹², -XC(O)NR¹¹R¹², -XOC(O)NR¹¹R¹², -XNR¹¹C(O)NR¹¹R¹², -XNR¹¹XOR¹², XN(XOR¹²)₂, -XNR¹¹XC(O)OR¹², -XNR¹¹XNR¹¹C(O)R¹², -XNR¹¹XNR¹¹R¹², -XNR¹¹C(O)R¹²; en donde cada X se selecciona independientemente a partir de un enlace y alquileno C₁₋₄; cada R¹¹ se selecciona a partir de hidrógeno y alquilo C₁₋₆; y R¹² se selecciona a partir de hidrógeno, alquilo C₁₋₆, y arilo C₆₋₁₀; o R¹¹ y R¹² junto con el átomo de nitrógeno con el que R¹¹ y R¹² están unidos, forman un heterocicloalquilo C₃₋₈; en donde el heteroarilo o heterocicloalquilo de R¹, R², R³, R⁴ o R⁵ está opcionalmente sustituido con 1 a 3 radicales independientemente seleccionados a partir de halógeno, hidroxilo, ciano, alquilo C₁₋₆, alquilo C₁₋₆ sustituido por halógeno, alquilo C₁₋₆ sustituido por hidroxilo, alquilo C₁₋₆ sustituido por ciano, y carboxilo; R⁶ y R⁷ se seleccionan independientemente a partir de hidrógeno y alquilo C₁₋₃; o R⁶ y R⁷, junto con el átomo de carbono con el que están ambos unidos, forman cicloalquilo C₃₋₇; R⁸ se selecciona a partir de alquilo C₁₋₆, alquilo C₁₋₃ sustituido por halógeno, alcoxilo C₁₋₆, -CH₂OR⁸ᵃ, -COOR⁸ᵃ, y alquenilo C₂₋₆; o dos grupos R⁸ unidos a diferentes átomos de carbono pueden combinarse para formar un puente de alquilo; o dos grupos R⁸ unidos al mismo átomo de carbono pueden formar un grupo cicloalquilo C₃₋₈ o un grupo carbonilo; en donde R⁸ᵃ se selecciona a partir de hidrógeno y alquilo C₁₋₆; R⁹ se selecciona a partir de arilo C₆₋₁₀, y heteroarilo C₁₋₁₀; en donde este arilo o heteroarilo de R⁹ está opcionalmente sustituido con 1 a 3 radicales independientemente seleccionados a partir de halógeno, ciano, hidroxilo, alquilo C₁₋₃, alquilo C₁₋₃ sustituido por halógeno, alquilo C₁₋₃ sustituido por ciano, alquilo C₁₋₃ sustituido por hidroxilo, -C(O)R¹³, -C(O)NR¹³R¹⁴; en donde cada R¹³ y R¹⁴ se seleccionan independientemente a partir de hidrógeno y alquilo C₁₋₆; R¹⁰ se selecciona a partir de hidrógeno, alquilo C₁₋₆, -NR¹⁵R¹⁶, -NR¹⁵C(O)R¹⁶ y -C(O)NR¹⁵R¹⁶; en donde cada R¹⁵ y R¹⁶ se seleccionan independientemente a partir de hidrógeno, alquilo C₁₋₆, arilo C₆₋₁₀, heteroarilo C₁₋₁₀, cicloalquilo C₃₋₁₂, y heterocicloalquilo C₃₋₈; en donde dichos arilo, heteroarilo, cicloalquilo, y heterocicloalquilo pueden estar opcionalmente sustituidos con 1 a 3 radicales independientemente seleccionados a partir de halógeno, hidroxilo, ciano, alquilo C₁₋₆, alquilo C₁₋₆ sustituido por halógeno, alcoxilo C₁₋₆, y alcoxilo C₁₋₆ sustituido por halógeno; Y y Z se seleccionan independientemente a partir de CR²⁰ y N; en donde R²⁰ se selecciona a partir de hidrógeno y alquilo C₁₋₄; y las sales farmacéuticamente aceptables de los mismos; con la condición de que los compuestos de la fórmula (1) no incluyen a los compuestos de la fórmula (2).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83268106P | 2006-07-21 | 2006-07-21 | |
| US89387407P | 2007-03-08 | 2007-03-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR062011A1 true AR062011A1 (es) | 2008-08-10 |
Family
ID=38727512
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070103248A AR062011A1 (es) | 2006-07-21 | 2007-07-20 | Derivados de diazol y sus composiciones como inhibidores de itpkb |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20090306039A1 (es) |
| EP (1) | EP2057124A2 (es) |
| JP (1) | JP2009544626A (es) |
| KR (1) | KR20090029274A (es) |
| AR (1) | AR062011A1 (es) |
| AU (1) | AU2007275049B2 (es) |
| BR (1) | BRPI0714440A2 (es) |
| CA (1) | CA2656715A1 (es) |
| CL (1) | CL2007002123A1 (es) |
| MX (1) | MX2009000771A (es) |
| PE (1) | PE20080405A1 (es) |
| RU (1) | RU2425826C2 (es) |
| TW (1) | TW200817375A (es) |
| WO (1) | WO2008011611A2 (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20090036573A (ko) * | 2006-07-04 | 2009-04-14 | 아스트라제네카 아베 | 신규한 피리딘 유사체 |
| EP2167498B1 (en) * | 2007-06-15 | 2010-09-15 | Irm Llc | Compounds and compositions as itpkb inhibitors |
| CA2720490A1 (en) * | 2008-04-04 | 2009-10-08 | Irm Llc | Compounds and compositions as itpkb inhibitors |
| US8853202B2 (en) | 2008-11-04 | 2014-10-07 | Chemocentryx, Inc. | Modulators of CXCR7 |
| MX2011004490A (es) * | 2008-11-04 | 2011-07-20 | Chemocentryx Inc | Moduladores de cxcr7. |
| BR102012024778A2 (pt) * | 2012-09-28 | 2014-08-19 | Cristalia Prod Quimicos Farm | Compostos heteroaromáticos; processo para preparar os compostos, composições farmacêuticas, usos e método de tratamento para as dores aguda e crônica |
| BR112015012366A8 (pt) | 2012-11-29 | 2019-10-01 | Chemocentryx Inc | antagonistas de cxcr7, uso dos mesmos, composição farmacêutica, bem como métodos para detectar níveis elevados de cxcr7 em uma amostra e para imagear um tumor, órgão, ou tecido |
| MX2015007205A (es) | 2012-12-06 | 2016-03-31 | Quanticel Pharmaceuticals Inc | Inhibidores de la desmetilasa de histona. |
| ES2608395T3 (es) | 2013-01-23 | 2017-04-10 | Astrazeneca Ab | Compuestos químicos |
| WO2015092009A1 (en) * | 2013-12-20 | 2015-06-25 | Laboratorios Del Dr. Esteve, S.A. | Piperazine derivatives having multimodal activity against pain |
| JP6769963B2 (ja) | 2014-08-29 | 2020-10-14 | ティエエッセ ファルマ ソチエタ レスポンサビリタ リミタータ | α−アミノ−β−カルボキシムコン酸セミアルデヒド脱炭酸酵素の阻害剤 |
| US10421756B2 (en) | 2015-07-06 | 2019-09-24 | Rodin Therapeutics, Inc. | Heterobicyclic N-aminophenyl-amides as inhibitors of histone deacetylase |
| RS62639B1 (sr) | 2015-07-06 | 2021-12-31 | Alkermes Inc | Hetero-halo inhibitori histonskih deacetilaza |
| MD3570834T2 (ro) | 2017-01-11 | 2022-04-30 | Alkermes Inc | Inhibitori biciclici ai histon deacetilazei |
| JP7152471B2 (ja) | 2017-08-07 | 2022-10-12 | ロダン・セラピューティクス，インコーポレーテッド | ヒストン脱アセチル化酵素の二環阻害剤 |
| US11464786B2 (en) | 2018-12-12 | 2022-10-11 | Chemocentryx, Inc. | CXCR7 inhibitors for the treatment of cancer |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2692575B1 (fr) * | 1992-06-23 | 1995-06-30 | Sanofi Elf | Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
| JP2781661B2 (ja) * | 1992-12-17 | 1998-07-30 | フアイザー・インコーポレイテツド | Ｃｒｆアンタゴニストとしての置換ピラゾール |
| DE69615376T2 (de) * | 1995-07-13 | 2002-09-05 | Knoll Gmbh | Piperazin-derivate als heilmittel |
| US6727264B1 (en) * | 2001-07-05 | 2004-04-27 | Synaptic Pharmaceutical Corporation | Substituted anilinic piperidines as MCH selective antagonists |
| GB0228417D0 (en) * | 2002-12-05 | 2003-01-08 | Cancer Rec Tech Ltd | Pyrazole compounds |
| WO2005019182A1 (en) * | 2003-08-20 | 2005-03-03 | Bayer Healthcare Ag | Pyrazolylmethylbenzamide derivatives as p2xt-receptor antagonists |
-
2007
- 2007-07-20 US US12/374,481 patent/US20090306039A1/en not_active Abandoned
- 2007-07-20 KR KR1020097001165A patent/KR20090029274A/ko not_active Abandoned
- 2007-07-20 PE PE2007000948A patent/PE20080405A1/es not_active Application Discontinuation
- 2007-07-20 TW TW096126677A patent/TW200817375A/zh unknown
- 2007-07-20 AR ARP070103248A patent/AR062011A1/es unknown
- 2007-07-20 CA CA002656715A patent/CA2656715A1/en not_active Withdrawn
- 2007-07-20 BR BRPI0714440-7A patent/BRPI0714440A2/pt not_active IP Right Cessation
- 2007-07-20 CL CL200702123A patent/CL2007002123A1/es unknown
- 2007-07-20 MX MX2009000771A patent/MX2009000771A/es active IP Right Grant
- 2007-07-20 EP EP07799749A patent/EP2057124A2/en not_active Withdrawn
- 2007-07-20 AU AU2007275049A patent/AU2007275049B2/en not_active Revoked
- 2007-07-20 JP JP2009521029A patent/JP2009544626A/ja not_active Withdrawn
- 2007-07-20 RU RU2009105829/04A patent/RU2425826C2/ru not_active IP Right Cessation
- 2007-07-20 WO PCT/US2007/074048 patent/WO2008011611A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| RU2009105829A (ru) | 2010-08-27 |
| BRPI0714440A2 (pt) | 2013-04-24 |
| CL2007002123A1 (es) | 2008-06-13 |
| US20090306039A1 (en) | 2009-12-10 |
| AU2007275049B2 (en) | 2011-03-03 |
| WO2008011611A2 (en) | 2008-01-24 |
| TW200817375A (en) | 2008-04-16 |
| AU2007275049A1 (en) | 2008-01-24 |
| KR20090029274A (ko) | 2009-03-20 |
| EP2057124A2 (en) | 2009-05-13 |
| PE20080405A1 (es) | 2008-06-18 |
| JP2009544626A (ja) | 2009-12-17 |
| WO2008011611A3 (en) | 2008-05-02 |
| RU2425826C2 (ru) | 2011-08-10 |
| MX2009000771A (es) | 2009-01-30 |
| CA2656715A1 (en) | 2008-01-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR062011A1 (es) | Derivados de diazol y sus composiciones como inhibidores de itpkb | |
| AR087760A1 (es) | Heterociclilaminas como inhibidores de pi3k | |
| AR091416A1 (es) | Diazaespirocicloalcanos y azaespirocicloalcanos como inhibidores de atx y de lpa | |
| AR088061A1 (es) | Compuestos de pirazol-4-il-heterociclil-carboxamida y metodos de uso | |
| AR113964A1 (es) | Carbamoíl ciclohexil ácidos ligados a n de triazol como antagonistas de lpa | |
| AR118374A1 (es) | Inhibidores de la proteína tirosina fosfatasa y métodos para usarlos | |
| AR113818A2 (es) | Pirazolo-quinazolinas como inhibidores de proteína quinasa | |
| AR087841A1 (es) | Derivados de tetrahidrotriazolopirimidina | |
| AR110139A1 (es) | COMPUESTOS MONO Y ESPIROCÍCLICOS QUE CONTIENEN CICLOBUTANO Y AZETIDINA COMO INHIBIDORES DE LA INTEGRINA aV | |
| AR092108A1 (es) | Piridazina 1,4 disustituida, analogos de la misma y metodos para tratar las enfermedades relacionadas con deficiencia del smn | |
| AR090945A1 (es) | Moduladores de la via del complemento y usos de los mismos | |
| AR090293A1 (es) | Inhibidores de quinasa a base de arileter | |
| AR112834A1 (es) | Derivados de rapamicina | |
| AR085748A1 (es) | Piridinonas biciclicas | |
| AR100438A1 (es) | Pirazolopiridinas y pirazolopirimidinas | |
| AR062050A1 (es) | Derivados de amina utiles como agentes anti-cancerigenos | |
| AR076486A1 (es) | Inhibidores de fosfoinositida 3 kinasa y composiciones farmaceuticas que los contienen. | |
| AR091279A1 (es) | Inhibidores macrociclicos de virus flaviviridae | |
| AR094346A1 (es) | Derivados de azaindol como inhibidores de las proteína quinasas | |
| AR044402A1 (es) | Compuestos heterociclicos y su uso como inmunodepresores. composiciones farmaceuticas que los contienen. | |
| AR070221A1 (es) | Derivados de ftalazinona inhibidores de polimerasas, composiciones farmaceuticas que los contienen y usos de los mismos para prevenir y/o tratar tumores cancerigenos,lesiones isquemicas y otras enfermedades asociadas. | |
| AR088293A1 (es) | Inhibidores de proteina cinasa | |
| AR092628A1 (es) | Piridinonas biciclicas | |
| AR091498A1 (es) | DERIVADOS DE 2,3-DIHIDRO-1H-IMIDAZO{1,2-a}PIRIMIDIN-5-ONA Y 1,2,3,4-TETRAHIDRO-PIRIMIDO{1,2-a}PIRIMIDIN-6-ONA QUE CONTIENEN UNA MORFOLINA SUSTITUIDA, SU PREPARACION Y SU UTILIZACION FARMACEUTICA | |
| AR094550A1 (es) | Inhibidores de btk |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |